A strain of Lactobacillus plantarum GLP1-LP that promotes the secretion of glucagon-like peptide

Abstract

The present invention belongs to the field of microorganisms and their application, and provides a Lactobacillus plantarum ( Lactobacillus plantarum ) GLP1-LP, whose deposit number is CGMCC No. 29590. The present invention also provides plant lactobacillus ( Lactobacillus plantarum ) Application of GLP1-LP in promoting the secretion of glucagon-like peptide-1 (GLP-1), inhibiting weight gain, and thus improving obesity and / or alleviating hyperglycemia. The Lactobacillus plantarum GLP1-LP provided by the present invention has excellent acid-base and bile salt tolerance. In cell experiments, the GLP1-LP strain can effectively activate the fatty acid receptor GPR120 and promote the secretion of GLP-1. In animal experiments, the Lactobacillus plantarum GLP1-LP strain showed good effects of reducing weight, inhibiting appetite, improving hyperglycemia, and increasing the level of GLP-1, which provides a good scientific basis for the future development of effective weight intervention products and has great potential market value.

Description

Technical Field

[0001] The invention belongs to the field of microorganisms and applications thereof, and particularly relates to Lactobacillus plantarum GLP1-LP and applications thereof. Background Art

[0002] Obesity is a chronic, complex and multifactorial disease. It is the fifth leading risk factor for global mortality, causing nearly 3.4 million deaths each year. Epidemiological studies have shown that more than 2.1 billion people are overweight or obese worldwide. If the current trend continues, it is estimated that by 2030, 38% of adults worldwide will be overweight and another 20% will become obese. Obesity is associated with a variety of serious complications. Like obesity, the incidence of diabetes has also risen sharply around the world and is becoming the leading cause of death in many countries. At present, obesity or overweight has had a serious impact on the physical health and quality of life of patients and individuals, and has also brought a major public health problem with a heavy economic burden to society. Therefore, improving obesity or overweight is not only an individual health problem, but also an urgent health problem that needs to be overcome by the whole society.

[0003] Fatty acid receptors are a class of receptors that can be activated by fatty acids and their derivatives. G protein-coupled receptor GPR120 (FFAR4) is a member of the fatty acid receptor family and an important drug target for metabolic syndromes such as obesity / diabetes. This receptor can recognize long-chain fatty acids, including common fatty acids such as ω-3 fatty acids, linoleic acid (LA) and oleic acid (OA) in fish oil. Previous studies have shown that GPR120 can promote the secretion of GLP1 through its downstream Gq signaling pathway, thereby promoting insulin secretion to achieve the purpose of lowering blood sugar; promote insulin and inhibit the release of ghrelin through the Gi signaling pathway; GPR120 in cilia can control fat formation through its downstream Gs signaling pathway; and can also play an anti-inflammatory role by mediating the β-arrestin2 signaling pathway. Therefore, GPR120 plays an important role in physiological processes such as anti-inflammatory effects, improving insulin sensitivity, promoting the secretion of GLP-1, controlling fat formation and bone differentiation.

[0004] GLP-1 drugs are a class of drugs used to treat type 2 diabetes and obesity. They can lower blood sugar levels by promoting insulin secretion, inhibiting glucagon secretion and slowing gastric emptying. They can also reduce appetite and promote satiety, which helps lose weight. The use of GLP-1 drugs often does not cause hypoglycemia (hypoglycemia is one of the common side effects of diabetes treatment). Despite this, GLP-1 drugs still have some disadvantages, including: (1) Injectable dosage form: Most GLP-1 drugs currently need to be administered by subcutaneous injection, which may not be convenient for some patients, especially for those who are not comfortable with injections. (2) Gastrointestinal side effects: GLP-1 drugs may cause gastrointestinal discomfort, such as nausea, vomiting and diarrhea, which may affect the patient's quality of life. (3) High cost: Some GLP-1 drugs are relatively expensive, which may limit their use in some patients. (4) Long-term safety: Although the short-term safety of GLP-1 drugs is relatively good, some long-term safety issues, such as pancreatitis and thyroid tumors, still need further research and monitoring. Therefore, researchers are constantly improving the formulation and dosage form of GLP-1 drugs and exploring the possibility of oral GLP-1 drugs to increase the convenience of patients' medication. Overall, although GLP-1 drugs have many advantages in treating diabetes and obesity, patients and doctors still need to weigh their pros and cons and choose the most appropriate treatment plan.

[0005] Probiotics are a general term for living microorganisms that are beneficial to the human body. Probiotics are highly safe, and normal use will not cause side effects to the body. They can also have a beneficial effect on maintaining the health of the body. Therefore, in recent years, the development and efficacy research of probiotics in the global market is in full swing. With the continuous improvement of people's health awareness, more and more people are beginning to pay attention to the relationship between intestinal health and physical health. Probiotics have attracted much attention for their benefits to intestinal health. The increase in income levels and changes in consumption habits have also prompted people to pay more attention to the choice of health products and functional foods. As a functional food, probiotics are widely favored by consumers. In recent years, scientific research and development on probiotics have also made breakthrough progress, laying a solid theoretical foundation for the development of this market. Most importantly, the Chinese government has taken a series of policy measures to promote the development of food safety and health, providing policy support and guidance for the healthy development of the probiotics market. It can be seen that selecting excellent strains that can activate GPR120 and promote the release of GLP-1 from the probiotics group widely accepted by the public will provide consumers with a safer and more convenient weight and blood sugar management strategy, and the development of related products will benefit the majority of people who are deeply troubled by overweight / obesity. Therefore, the development of new health management strategies and products based on probiotics has broad development prospects in my country. Summary of the invention

[0006] In order to solve the above problems existing in the prior art, the present invention provides a strain of Lactobacillus plantarum GLP1-LP, which can activate the GPR120 receptor, inhibit weight gain, and promote the release of glucagon-like peptide (GLP-1), and its application; the Lactobacillus plantarum GLP1-LP can significantly promote the secretion of GLP-1 by cells at the cellular level; at the animal level, the strain significantly reduces the body weight of obese mice, inhibits food intake, and has an excellent improvement effect on hyperlipidemia.

[0007] According to one aspect of the present invention, there is provided a Lactobacillus plantarum GLP1-LP ( Lactobacillus plantarum ) or its culture supernatant or its dead cells.

[0008] According to one aspect of the present invention, there is provided a use of the Lactobacillus plantarum GLP1-LP or its culture supernatant or its dead bacteria for activating the fatty acid receptor GPR120.

[0009] According to one aspect of the present invention, there is provided a use of the Lactobacillus plantarum GLP1-LP or its culture supernatant or its dead bacteria for promoting the secretion of glucagon-like peptide-1.

[0010] According to one aspect of the present invention, there is provided a use of the Lactobacillus plantarum GLP1-LP or its culture supernatant or its dead bacteria in the preparation of a product for inhibiting weight gain, suppressing appetite, lowering blood sugar and / or lowering serum TG, TC and LDL-c.

[0011] According to another aspect of the present invention, a bacterial agent is provided, the bacterial agent containing the Lactobacillus rhamnosus strain B2BY2 or its culture supernatant or dead bacteria. Preferably, the solid preparation or liquid preparation. Preferably, the solid bacterial agent is a powder prepared by freeze drying.

[0012] According to another aspect of the present invention, a method for preparing a product composition is provided, the method comprising: adding bacterial substances and / or metabolites of the Lactobacillus plantarum GLP1-LP to a product matrix to obtain the product composition.

[0013] Storage Instructions:

[0014] Strain name: GLP1-LP

[0015] Latin name: Lactobacillus plantarum

[0016] Classification name: Lactobacillus plantarum

[0017] Strain ID: 29590

[0018] Depository: China National Microbiological Culture Collection Administration General Microbiology Center

[0019] Abbreviation of depository institution: CGMCC

[0020] Address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing

[0021] Deposit date: January 15, 2024

[0022] CGMCC Registration Number: CGMCC No. 29590

[0023] The present invention provides plant lactobacillus ( Lactobacillus plantarum ) GLP1-LP can activate fatty acid receptors, promote the secretion of glucagon-like peptide GLP-1, inhibit weight gain and appetite, and has a good effect in improving hyperlipidemia. It provides a good scientific basis for the future development of effective and safe weight management and hyperlipidemia improvement products, and has great potential market value. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 The phylogenetic tree analysis of the Lactobacillus plantarum GLP1-LP strain of the present invention is shown.

[0026] Figure 2 The figure shows the apparent morphology of the Lactobacillus plantarum GLP1-LP strain of the present invention.

[0027] Figure 3 The figure shows the effect of the Lactobacillus plantarum GLP1-LP strain of the present invention on the activation of the intracellular GPR120 receptor.

[0028] Figure 4 The effect of the Lactobacillus plantarum GLP1-LP strain of the present invention on the intracellular GLP-1 level is shown.

[0029] Figure 5 The intervention effect of Lactobacillus plantarum GLP1-LP in the present invention on the body weight of obese mice is shown. (A) Mouse weight gain, (B) Mouse food intake, (C) Mouse serum TG level, (D) Mouse serum TC level, (E) Mouse LDL-c level. n=8, *p<0.05, **p<0.01, ***p<0.001.

[0030] Figure 6 The intervention effect of Lactobacillus plantarum GLP1-LP in the present invention on blood glucose in obese mice is shown. (A) Fasting blood glucose value of mice, (B) Serum GLP-1 level. n=8, *p<0.05, **p<0.01, ***p<0.001. DETAILED DESCRIPTION

[0031] To make the technical solution, purpose and advantages of the present invention clearer, the present invention is further described in detail below through specific implementation examples. It should be understood that the specific implementation methods described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.

[0032] Unless otherwise defined, all terms (including technical and scientific terms) used in the present invention have the same meaning as commonly understood by ordinary technicians in the field to which the present invention belongs. In the event of a conflict between the prior art and the present invention, the present invention shall prevail.

[0033] The various reagents, materials, etc. used in the following examples, unless otherwise specified, are all products that can be obtained from commercial channels; the various tests and detection methods used in the following examples, unless otherwise specified, are all conventional tests and detection methods in the art and can be obtained from textbooks, reference books or academic journals.

[0034] Example 1: Preparation of the Lactobacillus plantarum GLP1-LP strain of the present invention

[0035] 1.1 Isolation of Lactobacillus plantarum GLP1-LP strain

[0036] The Lactobacillus plantarum GLP1-LP strain of the present invention was isolated from the intestinal flora of healthy adults living in Beijing for a long time. The subjects had not taken antibiotics before collection and had no history of taking probiotics. Take 1 g of fecal sample, add 9 mL of normal saline (10 times dilution) and mix well, take 0.5 mL of the dilution, and dilute it again with normal saline to 10 times. -3 , take 100 μL of liquid (10 -1 , 10 -2 , 10 -3) was spread on solid MRS medium (10 g peptone, 10 g beef extract, 5 g yeast extract, 2 g diammonium citrate, 20 g glucose, 1 mL Tween 80, 5 g sodium acetate, 2 g dipotassium hydrogen phosphate, 0.58 g magnesium sulfate, 0.25 g manganese sulfate, 18 g agar, 1000 mL distilled water) for culture (culture temperature 37°C, culture time 48-72 h). A single colony was picked and inoculated on a solid MRS medium plate for further culture (culture temperature 37°C, culture time 48 h), and the solid MRS medium plate was repeatedly streaked and purified (culture temperature 37°C, culture time 48 h) to obtain multiple pure culture strains. All strains were identified by MOLDI-TOLF flight mass spectrometry and stored in the self-built strain resource library of Quantitative Health.

[0037] The GLP1-LP strain stored at -80°C was streaked on MRS solid medium, cultured anaerobically at 37°C for 24-48 hours, and then a single colony was cultured in liquid MRS medium. After anaerobic culture at 37°C for 48 hours, an activated GLP1-LP bacterial solution was obtained. The GLP1-LP bacterial precipitate was then used to extract DNA according to the kit instructions, and then shotgun sequencing was performed to identify the strain type. The sequence obtained by sequencing was quality controlled, spliced, and assembled. The evolutionary tree analysis showed that the GLP1-LP strain was closest to Lactobacillus plantarum in evolution ( Figure 1 ), accordingly, the GLP1-LP bacteria in the present invention is named as Lactobacillus plantarum Lactobacillus plantarum GLP1-LP strain, the colony and Gram stain morphology of this strain are as follows Figure 2 shown.

[0038] 1.2 Sample preparation of Lactobacillus plantarum GLP1-LP strain

[0039] Streak the Lactobacillus plantarum GLP1-LP glycerol tube strain on MRS medium, culture at 37°C for 18 h, activate for 2 generations, pick a single colony and transfer it to MRS liquid medium, culture at 37°C for 24 h, and obtain the live bacterial solution of Lactobacillus plantarum GLP1-LP. Centrifuge the prepared bacterial solution at 8000 rpm for 10 min to separate the supernatant and precipitate. After transferring the supernatant to a sterile centrifuge tube, you can obtain the culture supernatant sample for subsequent experiments and store it at 4°C for later use. Resuspend the bacterial precipitate with physiological saline to obtain a live bacterial suspension with live bacteria, and adjust it to the appropriate concentration required for animal experiments (such as 10 9 CFU / mL). The inactivated strain of Lactobacillus plantarum GLP1-LP can be obtained by treating the live bacteria at 70°C for 30 min.

[0040] The live bacterial suspension can also be obtained by other methods in the art, as long as the bacterial cells can be enriched from the culture solution, for example, by centrifugation and / or filtration.

[0041] Example 2: Analysis of acid-base and bile salt tolerance of the Lactobacillus plantarum GLP1-LP strain of the present invention

[0042] This example is used to evaluate the acid resistance, alkali resistance and bile salt resistance of Lactobacillus plantarum GLP1-LP, which has important guiding significance for the development of products of this strain.

[0043] 2.1 Artificial gastrointestinal fluid tolerance test

[0044] Preparation of artificial gastric juice: Add water to 1 mol / L hydrochloric acid to adjust the pH to 2.5. Take 100 mL of hydrochloric acid solution with a pH of 2.5, add 1 g of pepsin, and after it is fully dissolved, filter it with a 0.22 μm filter membrane to sterilize it for later use.

[0045] Preparation of artificial intestinal fluid: weigh 6.8 g KH2PO4, add 500 mL distilled water to dissolve, adjust the pH to 6.8 with 0.01 mol / L NaOH solution, transfer to a 1 L volumetric flask, add water to the scale, add 10 g trypsin, and after fully dissolving, filter with a 0.22 μm filter membrane to sterilize for use.

[0046] After the plant lactobacillus GLP1-LP of the present invention is activated by MRS culture for 2 generations, a single colony is picked and inoculated into a liquid MRS culture medium, and cultured at 37°C for 18 h as a seed solution for standby use. Take 0.5 mL of bacterial solution and add it to 4.5 mL of sterile artificial gastric juice and artificial intestinal juice, mix well, place it in a 37°C incubator and incubate it for 3 hours, take the culture solution of 0 h and 3 h for live bacteria count, and calculate the survival rate according to the formula. The formula is as follows: survival rate%=logarithm of live bacteria count at 3 h / logarithm of live bacteria count at 0 h*100%.

[0047] According to Table 1, after incubation in artificial gastric juice and artificial intestinal juice for 3 hours, the survival rates of Lactobacillus plantarum GLP1-LP were as high as 89.59% and 87.02%, respectively, indicating that the GLP1-LP strain of the present invention has a high acid-base tolerance and can better resist the damage of gastric juice and intestinal juice when taken by the body.

[0048] Table 1 Tolerance of GLP1-LP artificial gastrointestinal fluid

[0049]

[0050] 2.2 Bile salt tolerance experiment

[0051] After GLP1-LP was activated by MRS culture for 2 generations, a single colony was picked and inoculated into liquid MRS medium and cultured at 37°C for 18 h. The bacterial solution was centrifuged at 8000 rpm for 10 min, the supernatant was discarded, and an equal volume of PBS was added to prepare a bacterial suspension. 5 mL of the bacterial solution was mixed with 5 mL of 0%, 1%, 2% and 3% bile salts, respectively. After incubation at 37°C for 3 h, the viable bacteria were counted and the survival rate was calculated according to the formula, survival rate %= (C3 / C0)×100, where C3: the number of viable bacteria after treatment with different concentrations of bile salts, C0: the number of viable bacteria without bile salt treatment.

[0052] According to Table 2, after incubation for 3 hours at 1%, 2% and 3% bile salt concentrations, the survival rates of Lactobacillus plantarum GLP1-LP in the present invention were 60.3%, 35.0% and 12.72%, respectively; as the bile salt concentration increased, the bile salt tolerance of GLP1-LP gradually decreased.

[0053] Table 2 Bile salt tolerance of Lactobacillus plantarum GLP1-LP

[0054]

[0055] Example 3: Activation of fatty acid receptor GRP120 by Lactobacillus plantarum GLP1-LP strain

[0056] This example is used to evaluate the activation effect of Lactobacillus plantarum GLP-LP in the present invention on the fatty acid receptor GPR120 (also known as free fatty acid receptor FFAR4). After the receptor binds to GPR120, its Gq pathway and downstream signals are activated, which will lead to an increase in intracellular calcium ion content. The surge in intracellular calcium ion levels promotes intracellular exocytosis, thereby promoting the secretion of GLP-1.

[0057] The mouse small intestinal endocrine cell line STC-1 was cultured and passaged according to normal cell culture operations. During the experiment, the STC-1 cells were transferred to a 96-well cell culture plate. When the cells grew to a confluence of 70-80%, the culture supernatant (different volume fractions) of the Lactobacillus plantarum GLP1-LP of the present invention was incubated and co-cultured with the STC-1 cells in a 37°C incubator. After 18-22 hours, the culture medium was discarded and replaced with a culture medium containing a calcium ion fluorescent indicator Fluo-4 AM for light-proof staining for 30 minutes, and then the dye was discarded, and the cells were washed three times with sterile PBS, and the last PBS was retained and then read with an enzyme reader (excitation light 494nm, emission light 516nm).

[0058] according to Figure 3The results showed that compared with blank MRS medium, after adding Lactobacillus plantarum GLP1-LP culture supernatant, the fluorescence intensity in STC-1 cells gradually increased with the increase in the amount of supernatant added, showing an obvious dose-dependent effect. The fluorescence intensity in the cells was the highest after treatment with 20% (v / v) added GLP1-LP supernatant, indicating that the calcium ion content in the cells was the highest after adding 20% ​​(v / v) strain culture supernatant, indirectly indicating that the activation of GPR120 was the strongest.

[0059] Example 4: Promoting effect of Lactobacillus plantarum GLP1-LP strain on GLP-1 secretion

[0060] This example is used to evaluate the promoting effect of Lactobacillus plantarum GLP-LP in the present invention on the secretion of GLP-1 (glucagon-like peptide-1), a downstream effector after GPR120 activation.

[0061] The STC-1 cells were transferred to a 96-well cell culture plate, and when the cells grew to a confluence of 70-80%, the culture supernatant (different volume fractions) of the plant lactobacillus GLP1-LP in the present invention was incubated and co-cultured with the STC-1 cells in a 37°C incubator. After 18-22 hours, the culture medium was collected, and then centrifuged at 1000 r / min for 10 min at 4°C, cell debris and other precipitates were discarded, and the supernatant after centrifugation was collected and stored at -80°C for use. During the experiment, an ELISA kit for detecting GLP-1 was used, and the detection was performed according to the product instructions.

[0062] according to Figure 4 The results showed that compared with the blank MRS culture medium, the GLP-1 content in the supernatant of STC-1 cells increased significantly after the addition of Lactobacillus plantarum GLP1-LP culture supernatant, showing a certain dose-dependent effect. When 20% (v / v) of GLP1-LP culture supernatant was added, the average level of GLP-1 secreted by the cells was about 52.1 pM, indicating that the Lactobacillus plantarum GLP1-LP culture fluid of the present invention can effectively promote the production of GLP-1 by mouse small intestinal endocrine cells. This result also proves the activation of the GPR120 receptor by the GLP1-LP strain.

[0063] Example 5: Intervention effect of Lactobacillus plantarum GLP1-LP on obese mice

[0064] This example illustrates the improvement effect of Lactobacillus plantarum GLP1-LP on obesity symptoms in mice fed a high-fat diet at the animal level.

[0065] The mice used were purchased from Beijing Weitonglihua. Forty 8-week-old male C57BL / 6 mice were randomly divided into four groups: normal group, model group, high-fat + GLP1-LP live bacteria suspension group, and high-fat + GLP1-LP dead bacteria suspension group, with 8 animals in each group. The normal group was fed with standard mouse feed, and the other groups were fed with 60% fat-functional high-fat feed. The high-fat + GLP1-LP live bacteria group was fed 1×10 9 CFU corresponding GLP1-LP live bacterial suspension; the high-fat + GLP1-LP dead bacteria group was given a pasteurized live bacterial heavy suspension every day, and the model group was given an equal volume of normal saline. The bacteria were given continuously for 8 weeks, and the weight data were recorded after weighing the mice every week, and the food intake of mice in each group was recorded. After 8 weeks, the mice were fasted overnight, and the fasting blood glucose of the mice was measured the next day. Then they were anesthetized with chloral hydrate, blood was collected from the orbits, and the supernatant was taken as a serum sample after centrifugation at 4°C for measuring the levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and GLP-1 in the serum. The animals were killed at the same time.

[0066] according to Figure 5 It can be seen that continuous feeding of high-fat diet for 8 weeks can lead to a significant increase in the body weight of mice ( Figure 5 A), showing that a high-fat diet can significantly promote the occurrence of obesity; the weight gain of mice in the group gavaged with GLP1-LP strain (live and dead bacteria) was significantly inhibited, and the effect of live bacteria was slightly better than that of dead bacteria. Statistics on the food intake of mice showed that gavage with GLP1-LP strain (live and dead bacteria) could significantly reduce the food intake of mice, which was consistent with the trend of body weight. The effect of live bacteria was slightly better than that of dead bacteria, indicating that Lactobacillus plantarum GLP1-lP has the effect of inhibiting weight gain and appetite in obese mice ( Figure 5 B). The serum test results showed that the levels of triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) in the serum of the model group animals increased, showing an obvious hyperlipidemia phenotype. After intragastric administration of the GLP1-LP live bacterial suspension or dead bacterial suspension provided by the present invention, the blood lipid level was significantly lower than that of the model group ( Figure 5 CE). These results show that feeding mice with the Lactobacillus plantarum GLP1-LP provided by the present invention can significantly inhibit the weight gain caused by a high-fat diet, suppress appetite, and reduce the serum TG, TC and LDL-c levels of animals, showing a good effect of improving obesity.

[0067] The fasting blood glucose of obese mice after 8 weeks of treatment was tested and it was found that ( Figure 6), after oral administration of GLP1-LP strain, the average fasting blood glucose of mice decreased from 10.29 mmol / L to 8.17 mmol / L (live bacteria group) and 9.31 mmol / L (dead bacteria group), and blood glucose abnormalities were improved. Consistent with this, the serum glucagon-like peptide-1 (GLP-1) content was increased in mice with oral administration of the strain. This result is similar to the results of cell experiments that GLP1-LP culture supernatant can activate GPR120 receptors and stimulate mouse small intestinal endocrine cells to secrete GLP-1.

[0068] The above animal experimental results show that the Lactobacillus plantarum GLP1-LP strain in the present invention can not only suppress appetite and reduce body weight, but also improve blood sugar by promoting the secretion of GLP-1. These effects provide an important theoretical basis for the development of the strain, contribute to the development of related food products, and have great market application prospects.

[0069] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A Lactobacillus plantarum ( Lactobacillus plantarum )GLP1-LP, the deposit number of the plant lactobacillus is CGMCC No. 29590.

2. Use of the Lactobacillus plantarum GLP1-LP according to claim 1 in preparing a product for inhibiting weight gain, suppressing appetite, lowering blood sugar and / or lowering blood lipids.

3. A bacterial agent, comprising the Lactobacillus plantarum GLP1-LP according to claim 1.

4. The bacterial agent according to claim 3, wherein The bacterial agent is a solid preparation or a liquid preparation.

5. The bacterial agent according to claim 3, wherein The solid preparation is a powder prepared by freeze-drying.

6. A method for preparing a product composition, characterized in that: The method comprises: adding the bacterial substance of Lactobacillus plantarum GLP1-LP according to claim 1 to a product matrix to obtain the product composition.

Images